Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Koshiol J, Yu B, Kabadi S, Baria K, Shroff RT. Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015. BioMed Central. 2022. https://doi.org/10.1186/s12885-022-10286-z.
2. Shang P, Yu Y, Yan P, Xu H. [Retracted] therapeutic effect and prognosis of biliary tract tumor transformation. Comput Mathemat Methods Med. 2022;2022(1):9489003.
3. Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C et al. Biliary tract cancers: molecular heterogeneity and new treatment options. Cancers. 2020;12(11):3370.
4. Primrose J, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Elsevier BV. 2019;20(5):663–73. https://doi.org/10.1016/s1470-2045(18)30915-x.
5. Schweitzer N, Fischer M, Kirstein MM, Berhane S, Kottas M, Sinn M et al. Risk estimation for biliary tract cancer: Development and validation of a prognostic score. Liver Int. 2017;37(12):1852–60.